Skip to content
RDL Network logo
167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) — María Reig (2024) | RDL Network